Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported.
AMA J Ethics. 2019;21(11):E968-973. doi:
10.1001/amajethics.2019.968.
Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?